☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
triple negative breast cancer
AstraZeneca Signs an Agreement with Daiichi Sankyo to Develop and Commercialize DS-1062 Worth Up to $6B
July 27, 2020
OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer
May 23, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.